(Total Views: 738)
Posted On: 05/11/2020 11:35:20 AM
Post# of 153989
AGC & Samsung Biologics ready to ramp up!
AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab
by Diane Hunt on 4/29/20 3:49 PM
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
http://www.agcbio.com/resource-center/news/ag...leronlimab
Samsung NR excerpt:
Overall, the company reported stable business performance resulting from further utilization improvement at Plant 1 and Plant 2 due to increased market demands. Samsung Biologics continued its business development, client audit and inspection activities through innovative live virtual tours and due diligence, and as a result, the company signed ten new projects in the quarter with local and global clients.
https://www.biospectrumasia.com/news/51/15855...pport.html
CYDY lets get 1st Compassionate Use in May; 2nd EUA approval June!
Samsung & AGC Biologics delivery by June or July for more than 1,2 vials and PPS will take care of itself.
IMO
AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab
by Diane Hunt on 4/29/20 3:49 PM
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
http://www.agcbio.com/resource-center/news/ag...leronlimab
Samsung NR excerpt:
Overall, the company reported stable business performance resulting from further utilization improvement at Plant 1 and Plant 2 due to increased market demands. Samsung Biologics continued its business development, client audit and inspection activities through innovative live virtual tours and due diligence, and as a result, the company signed ten new projects in the quarter with local and global clients.
https://www.biospectrumasia.com/news/51/15855...pport.html
CYDY lets get 1st Compassionate Use in May; 2nd EUA approval June!
Samsung & AGC Biologics delivery by June or July for more than 1,2 vials and PPS will take care of itself.
IMO
(3)
(0)
